Neuroprotection as a treatment for glaucoma: Pharmacological and immunological approaches
Eur J Ophthalmol 2001; 11 (Suppl. 2): S7 - S11
Animal and culture models of glaucoma for studying neuroprotection
Eur J Ophthalmol 2001; 11 (Suppl. 2): S23 - S29
Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma
Eur J Ophthalmol 2001; 11 (Suppl. 2): S30 - S35
Brimonidine?s neuroprotective effects against transient ischaemia-induced retinal ganglion cell death
Eur J Ophthalmol 2001; 11 (Suppl. 2): S36 - S40
Electrophysiological approaches for early detection of glaucoma
Eur J Ophthalmol 2001; 11 (Suppl. 2): S41 - S49
Measuring structural changes in the optic nerve head and retinal nerve fibre layer
Eur J Ophthalmol 2001; 11 (Suppl. 2): S50 - S56
Evaluation of glaucomatous visual field loss with locally condensed grids using fundus-oriented perimetry (FOP)
Eur J Ophthalmol 2001; 11 (Suppl. 2): S57 - S62
Beta-adrenergic antagonists in the treatment of glaucoma
Eur J Ophthalmol 2001; 11 (Suppl. 2): S63 - S66
Influence of Topical Brimonidine on Visual Field in Glaucoma
Eur J Ophthalmol 2001; 11 (Suppl. 2): S67 - S71
Brimonidine (Alphagan?: a clinical profile four years after launch
Eur J Ophthalmol 2001; 11 (Suppl. 2): S72 - S77